First, the studies included in the meta-analysis by Kitson et al. [1] were performed in America, Europe, Australian, or Israel, all of which are predominantly white in skin color. A community-based cross-sectional study showed that, compared with whites, blacks had lower levels of vitamin D and vitamin D-binding protein [3] . In addition, potential differences of the influence of vitamin D status in the degree of hepatic fibrosis in CHC patients between whites and blacks were also observed [4] . As a consequence, levels and benefits of vitamin D might vary in individuals with different ethnicity, leading to question whether the irrelevance between vitamin D and SVR, and the ineffectivity of vitamin D in CHC, can also apply to other races.
Second, this meta-analysis only summarized eleven studies, seven of which with 1,951 patients were published articles and the other four were conference abstracts with less convincing evidence. Among the eleven studies, the sole outlier identified by funnel and forest plots just belonged to conference abstract. Another contemporaneous meta-analysis with eleven full-text studies demonstrated that a lower level of vitamin D was significantly associated with a lower probability of SVR in CHC patients receiving PEG-IFNα/ribavirin therapy, especially when a cutoff value of 20 ng/mL for vitamin D deficiency was adopted [5] . Furthermore, low vitamin D status was also found to be associated with a higher risk of advanced liver fibrosis in these patients [5] . Numerous clinical evidence also suggested that vitamin D supplementation might protect against disease progression and elevate the SVR rate following treatment for CHC [6, 7] . Recurrence of hepatitis C after liver transplantation is universal worldwide [8] . In addition to its association with primary CHC, vitamin D insufficiency could also result in a low SVR in patients with recurrent hepatitis C following antiviral therapy while vitamin D supplementation significantly improves the probability of achieving a SVR [8] .
Potential mechanisms that link vitamin D and CHC are complex and manifold.
Treatment with vitamin D reduces the extra-and intracellular levels of hepatitis C virus (HCV) core antigen in a dose-dependent manner [9] and produces calcitriol which could remarkably inhibit HCV productions [10] , suggesting that vitamin D plays a natural antiviral role. In addition, the anti-inflammatory effects by reducing several proinflammatory factors like TNF-α, IFN-γ, and IL-17, as well as the anti-fibrotic role of vitamin D [7] , might also partly explain the benefits of this vitamin supplementation in CHC. 
Conflicts of interest

